Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 2, 2014, Pages 129-135

  Hoppensteadt, Debra ^a   Tsuruta, Kazuhisa ^b   Cunanan, Josephine ^a   Hirman, Joe ^c   Kaul, Inder ^b   Osawa, Yutaka ^b   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

^c Pacific Northwest Statistical Consulting   (United States)

Author keywords

disseminated intravascular coagulation; hypercoagulable; sepsis associated coagulopathy; thrombomodulin

Indexed keywords

D DIMER; PROTHROMBIN; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ARTICLE; BLOOD CLOTTING DISORDER; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITALIZATION; PRIORITY JOURNAL; SEPSIS;

DISSEMINATED INTRAVASCULAR COAGULATION; HYPERCOAGULABLE; SEPSIS-ASSOCIATED COAGULOPATHY; THROMBOMODULIN;

ANTITHROMBIN III; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; RECOMBINANT PROTEINS; SEPSIS; THROMBIN; THROMBOMODULIN;

EID: 84893461044     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613492875     Document Type: Article

References (20)

1. Ralph AG, Brainard BM. Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it. Top Companion Anim Med. 2012 ; 27 (2). 65-72
2. Saracco P, Vitale P, Scolfaro C, Pollio B, Pagliarno M, Timeus F. The coagulopathy in sepsis: significance and implications for treatment. Pediatr Rep. 2011 ; 3 (4). e30
3. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006 ; 4: 4
4. Kaneko T, Wada H. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematopathol. 2011 ; 51 (2). 67-76
5. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 (5). 1327-1330
6. Levi M, De Jonge E, Van der Poll T. New treatment strategies for disseminated intravascular coagulation based current understanding of the pathophysiology. Ann Med. 2004 ; 36 (1). 41-49
7. AlanicC. An update on activated protein C (xigris) in the management of sepsis. http://www.ncbi.nlm.nih.gov/pmc/artciles/PMC2957744/. Accessed December 19, 2012.
8. Fareed J, Hoppensteadt D, Cunanan J, Adiguzel C, Kaul I.. Dysregulation of inflammatory and hemostatic markers in sepsis associated disseminated intravascular coagulation. Blood. 2012 ; 120 (21). 2223
9. Levi M, Van der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol. 2013 ; 79 (3). 294-298
10. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation; results of a phase III, randomized, double-blind clinical trial. J Thromb Hemost. 2007 ; 5 (1). 31-41
11. Ogawa Y, Yamakawa K, Ogura H, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Surg. 2012 ; 72 (5). 1150-1157
12. Vincent Jl, Ramesg MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, phase-2B study to evaluate the safety and efficacy of recombinant human thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. In press ;:
13. Lachin JM.. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials. 1999 ; 20 (5). 408-422
14. Tsuruta K, Yamada Y, Serada M, Tanigawara Y. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects. J Clin Pharmacol. 2011 ; 51 (9). 1276-1285
15. Moll S, Lindley C, Pescatore S, et al. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Heamost. 2004 ; 2 (10). 1745-1751
16. Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Haematologica. 1999 ; 84 (3). 254-259
17. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (Activated) in adults with septic shock. N Engl J Med. 2012 ; 366 (22). 2055-2064
18. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis. JAMA. 2001 ; 286 (15). 1869-1878
19. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med. 2005 ; 11 (5). 475-477
20. ClinicalTrials.gov. Safety and Efficacy of ART-123 in Subjects with Sepsis and Disseminated Intravascular Coagulation. http://clinicatrials.gov/ct2/ show/NCT00487656?term=art-123+AND+Sepsis+AND+dic&rank=2